PEDIATRICS Vol. 85 No. 3 March 1990, pp. 241-245
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chase, H. P.
Right arrow Articles by O'Brien, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chase, H. P.
Right arrow Articles by O'Brien, D.

Cyclosporine A for the Treatment of New-Onset Insulin-Dependent Diabetes Mellitus

H. Peter Chase MD1, Nancy Butler-Simon MS, RN1, Satish K. Garg MD1, Anthony Hayward MD, PhD1, Georgeanna J. Klingensmith MD1, Richard F. Hamman MD, DrPH1, and Donough O'Brien MD1

1 From the Department of Pediatrics and Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Barbara Davis Center for Childhood Diabetes, Denver

It is not known whether early immunosuppresive treatment can preserve long-term endogenous insulin secretion in subjects with insulin-dependent diabetes mellitus. In the present study, clinical remissions during the first year and C-peptide production for 3 years were followed after 43 subjects with newly diagnosed insulin-dependent diabetes mellitus were randomly assigned to a cyclosporine A treatment group for 4 months or to a control group. Of the six cyclosporine A-treated subjects who had remissions, five were 19 years of age or younger, compared with two of the four in the control group. C-peptide production was present in 98% of all subjects after 4 months, in 88% after 1 year, and in 43% after 3 years. There were no significant differences in numbers of subjects with C-peptide production or in mean hemoglobin A1 levels, between cyclosporine A-treated and control subjects after 3 years. Cyclosporine A treatment of subjects with newly diagnosed insulin-dependent diabetes mellitus for a period of 4 months does not have the ability to preserve residual beta-cell function.

Key Words: insulin-dependent diabetes mellitus • cyclosporine A • C-peptide

Submitted on June 15, 1989
Accepted on October 4, 1989




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
H. P. Chase, K. R. Crews, S. Garg, M. J. Crews, K. J. Cruickshanks, G. Klingensmith, E. Gay, and R. F. Hamman
(Outpatient Management vs In-Hospital Management of Children with New-Onset Diabetes
Clinical Pediatrics, August 1, 1992; 31(8): 450 - 456.
[Abstract] [PDF]

Home page
 JWatch GeneralHome page
FAILURE OF CYCLOSPORINE A IN NEW INSULIN-DEPENDENT DIABETES
Journal Watch (General), March 9, 1990; 1990(309): 2 - 2.
[Full Text]